EGFR inhibitor
CRIPTO1 expression in EGFR mutant NSCLC elicits intrinsic EGFR inhibitor resistance
... cell membrane–anchored protein that belongs to the EGF-CFC fam- ily (25, 26). CRIPTO1 was originally isolated from human undiffer- entiated NTERA-2 embryonic carcinoma cells and is not expressed in most adult tissues ...
14
Effects of EGFR inhibitor on helicobacter pylori induced gastric epithelial pathology in vivo
... selective EGFR inhibitor improves gastric corpus pathology and precancerous lesions and substantially decreases both the antral and corpus epithelial to apoptosis ratios to those of uninfected ...EFGR ...
21
Original Article Gefitinib, an EGFR inhibitor, prevents liver fibrosis development of mice
... whether EGFR inhibitor can ameliorate liver fibrosis, we injected the EGFR tyrosine kinase inhibitor Gifitinib to mice with liver fibrosis induced by ...
7
EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells
... Background: The purpose of the present study is to investigate the direct biological effects of the epidermal growth factor receptor (EGFR) inhibitor C225 on the radiosensitivity of human lung squamous ...
7
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
... selective EGFR inhibitor CNX-2006 in several representative preclinical models of ...of EGFR is achieved in the presence of the T790M ...of EGFR is still under ...NF-κB-mediated ...
16
Research progress on criteria for discontinuation of EGFR inhibitor therapy
... Abstract: The clinical success of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as therapeutic agents has prompted great interest in their further development and clinical testing ...
8
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
... MEK inhibitors [2]. Characteristic inflammatory papulo- pustular exanthemas, often described as acneiform or rosaceaform rashes, are the most frequent adverse effect associated with the use of EGFR-inhibtors ...
7
In Silico Analysis of Picfeltarraenin IA and IB as Potential PI3K and EGFR Inhibitor
... and EGFR target with compounds using docking procedure revealed that all the computationally predicted lowest energy complexes of PI3K and EGFR are stabilized by intermolecular hydrogen bonds and stacking ...
5
<p>Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway</p>
... STAT3 inhibitor LY5 and the EGFR inhibitor erlotinib on human CRC cells was inves- tigated in the HCT116 and DLD-1 CRC cell lines treated with STAT3 inhibitor LY5 and erlotinib, separately or ...
11
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
... MEKi, EGFR inhibitor (EGFRi), murine PD-L1 inhibitor (PD-L1i) and their combination ...kinase inhibitor as EGFRi that is able to recognize and inhibit the mouse ...with EGFR and PD-L1 ...
18
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
... including EGFR and FGFR families, cytokines and hormones [26, ...undescribed EGFR-I645L mutation in 97-H cell ...that EGFR-I645L is an activating mutation, sup- ported by the constitutive expression ...
15
EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy
... kinase inhibitor erlotinib or lapatinib significantly enhanced the cytotoxic effects of DNA-damaging agents compared to coadministration of the EGFR inhibitor and DNA-damaging ...that EGFR ...
10
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition
... to EGFR inhibition retain oncogenic stress that requiring PLK1 compensation (Figure 7E, upper ...and EGFR inhibitor represent orthogonal therapeutic agents, with enhanced tumoricidal activity when ...
17
Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
... of EGFR inhibitor treat- ment, suffered from complications or a history of dermopathy in extensive regions, had hemopathies with hemorrhagic symptoms, had used topical agents with retinoid-like effects ...
9
Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells
... of EGFR in the PD98059-induced TF ...the EGFR inhibitor erlotinib indeed suppressed PD98059-induced TF ...using EGFR siRNA gave similar ...enhanced EGFR activity, which in turn ...
10
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non small cell lung cancer and ovarian cancer: a systematic review
... There are substantial technical difficulties impeding progress in this regard –time and cost primary among them– but nonetheless the number of studies employing ‘biomic’ technologies to cancer cell lines or tissue ...
44
Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
... The oncogene BRAF is a recognized therapeutic target in CRC. The development of small-molecule inhibitors of RAF and the novel strategy for drug combinations have prolonged the survival of CRC subjects harboring BRAFm. ...
13
Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
... of EGFR in cancer cells in the absence of extracellular ligands (under serum free conditions) is well known; however, it is not clear regarding whether this activation of EGFR is sustained by extracellular ...
12
Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer
... down-regulated EGFR expression (Figure 1B), an important oncoprotein in lung ...HDAC inhibitor (HDACi) SAHA could induce c-Cbl expression (Supplementary Figure S1A and Figure ...
12
Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
... Abstract: Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, ...
9